Bristol Myers Squibb vs ImCheck Therapeutics
Bristol Myers Squibb vs ImCheck Therapeutics, compared side by side on 17 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Bristol Myers Squibb is on 22/100 and ImCheck Therapeutics on 60/100.
Where each one leads
Bristol Myers Squibb
- agent readiness: 44/100 against 34/100
- domain rating: 83/100 against 37/100
- headcount: 38,080 against 47
- LinkedIn following: 1,886,144 against 11,647
ImCheck Therapeutics
- our overall score: 60/100 against 22/100
At a glance
| Measure | Bristol Myers Squibb | ImCheck Therapeutics |
|---|---|---|
| What it is | A global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for patients with serious diseases. | ImCheck Therapeutics is a clinical-stage immuno-oncology company developing novel antibody therapies. |
| Category | Biotech, MedTech, HealthTech, Drug Discovery | Biotech, MedTech, HealthTech, Drug Discovery |
| Sells toBusiness model | B2B | B2B |
| Offering | Services | Biotech |
| Founded | 1989 | 2015 |
| Headquarters | New York, United States | Marseille, France |
| Status | Active | Active |
Size, funding and growth
| Measure | Bristol Myers Squibb | ImCheck Therapeutics |
|---|---|---|
| Employees | 38,080 | 47 |
| Total funding | Not published | $164M |
| LinkedIn followers | 1,886,144 | 11,647 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | Bristol Myers Squibb | ImCheck Therapeutics |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 22/100 | 60/100 |
| Traction | 20/100 | 57/100 |
| Team | 10/100 | 70/100 |
| Community | Not published | 15/100 |
| Search visibility | 23/100 | 22/100 |
| Quality | Not published | 68/100 |
| Agent readinessHow well an AI agent can read and act on the site | D (44/100) | F (34/100) |
| Domain ratingLink authority, 0-100 | 83/100 | 37/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | Bristol Myers Squibb | ImCheck Therapeutics |
|---|---|---|
| Hosting | Self Managed | Self Managed |
| CDN | CloudFront | Not detected |
| Frameworks | Not detected | Jquery, Tailwind CSS, Bootstrap |
| Analytics | Microsoft Clarity, Qualtrics | Google Analytics 4 |
What users say
| Measure | Bristol Myers Squibb | ImCheck Therapeutics |
|---|---|---|
| Reddit sentimentThreads we track | 2 positive, 3 negative across 6 threads | Not published |
“Bristol Myers Squibb ist im Kurs gerade günstig und spuckt aktuell über 5% Rendite durch Dividende (vierteljährlich) im Jahr aus. Nichts aufregendes, aber ne solide Bank und nicht vergessen... mühsam ernährt sich das Eichhörnchen.”r/Aktien
Bristol Myers Squibb vs ImCheck Therapeutics: common questions
Which is better, Bristol Myers Squibb or ImCheck Therapeutics?
On our 0-100 score ImCheck Therapeutics rates higher (60/100 against 22/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 17 data points above: read the rows that match what you are buying for.
How do Bristol Myers Squibb and ImCheck Therapeutics compare on the numbers?
Bristol Myers Squibb leads on agent readiness (44/100 against 34/100), domain rating (83/100 against 37/100), headcount (38,080 against 47), LinkedIn following (1,886,144 against 11,647). ImCheck Therapeutics leads on our overall score (60/100 against 22/100).
What do real users say about Bristol Myers Squibb and ImCheck Therapeutics?
Bristol Myers Squibb: 2 positive and 3 negative mentions across 6 Reddit threads we track, mostly in r/Aktien.
Read the full Bristol Myers Squibb review and pricing or the ImCheck Therapeutics review and pricing. You can also browse other Bristol Myers Squibb alternatives we track.